IL201082D0 - Bispecific antibodies and methods for production thereof - Google Patents

Bispecific antibodies and methods for production thereof

Info

Publication number
IL201082D0
IL201082D0 IL201082A IL20108209A IL201082D0 IL 201082 D0 IL201082 D0 IL 201082D0 IL 201082 A IL201082 A IL 201082A IL 20108209 A IL20108209 A IL 20108209A IL 201082 D0 IL201082 D0 IL 201082D0
Authority
IL
Israel
Prior art keywords
production
methods
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
IL201082A
Other versions
IL201082A (en
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US92084007P priority Critical
Priority to DKPA200700491 priority
Priority to PCT/DK2008/000124 priority patent/WO2008119353A1/en
Application filed by Genmab As filed Critical Genmab As
Publication of IL201082D0 publication Critical patent/IL201082D0/en
Publication of IL201082A publication Critical patent/IL201082A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
IL201082A 2007-03-29 2009-09-21 Bispecific antibodies and methods for production thereof IL201082A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US92084007P true 2007-03-29 2007-03-29
DKPA200700491 2007-03-29
PCT/DK2008/000124 WO2008119353A1 (en) 2007-03-29 2008-03-28 Bispecific antibodies and methods for production thereof

Publications (2)

Publication Number Publication Date
IL201082D0 true IL201082D0 (en) 2010-05-17
IL201082A IL201082A (en) 2017-04-30

Family

ID=39672666

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201082A IL201082A (en) 2007-03-29 2009-09-21 Bispecific antibodies and methods for production thereof

Country Status (11)

Country Link
US (2) US9212230B2 (en)
EP (2) EP2139924B1 (en)
JP (2) JP5681482B2 (en)
CN (2) CN101802015B (en)
AU (1) AU2008234248C1 (en)
CA (1) CA2681974C (en)
ES (2) ES2667863T3 (en)
IL (1) IL201082A (en)
MX (1) MX2009010282A (en)
NZ (1) NZ614857A (en)
WO (1) WO2008119353A1 (en)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
JP5144499B2 (en) 2006-03-31 2013-02-13 中外製薬株式会社 Antibody modification method for purifying bispecific antibodies
ES2667863T3 (en) 2007-03-29 2018-05-14 Genmab A/S Bispecific antibodies and their production methods
MX336725B (en) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr.
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
WO2009103791A1 (en) * 2008-02-22 2009-08-27 Genmab A/S Methods for assissing the risk of adverse events upon treatment with igg4 antibodies
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
WO2010107110A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN103796678B (en) * 2011-04-20 2018-02-27 健玛保 For HER2 bispecific antibody
CN103097417B (en) * 2010-04-20 2019-04-09 根马布股份公司 Albumen of the FC containing heterodimeric antibodies and preparation method thereof
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
AU2013203221B2 (en) * 2010-04-20 2016-06-02 Genmab A/S Heterodimeric antibody FC-containing proteins and methods for production thereof
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
MX346731B (en) 2010-04-23 2017-03-30 Genentech Inc * Production of heteromultimeric proteins.
WO2011143545A1 (en) * 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス,インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
HUE038305T2 (en) 2010-11-17 2018-10-29 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US20120183527A1 (en) * 2011-01-18 2012-07-19 Baxter International Inc. Measurement of anti-amyloid antibodies in human blood
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012271845B2 (en) * 2011-06-13 2017-07-27 Altrubio Inc. Anti-PSGL-1 antibodies and uses thereof
SG10201605572TA (en) 2011-07-06 2016-09-29 Genmab Bv Antibody variants and uses thereof
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
BR112014008684A2 (en) * 2011-10-11 2019-10-15 Genentech Inc heteromultimeric protein production methods and compositions
CN110964115A (en) * 2011-10-27 2020-04-07 健玛保 Production of heterodimeric proteins
MX358862B (en) 2011-11-04 2018-09-06 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain.
CN108424456A (en) 2011-11-23 2018-08-21 医学免疫有限责任公司 It is specific to the binding molecule and application thereof of HER3
DK2838918T3 (en) 2012-04-20 2019-08-12 Merus Nv METHODS AND METHODS FOR PREPARING HETERODIMER IG-LIKE MOLECULES
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
LT2844672T (en) 2012-05-03 2020-04-10 Regeneron Pharmaceuticals, Inc. Human antibodies to fel d1 and methods of use thereof
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
EP2859019B1 (en) * 2012-06-08 2018-02-21 Glenmark Pharmaceuticals S.A. Humanized anti-trka antibodies with amino acid substitutions
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CN104471397B (en) * 2012-07-13 2018-03-23 弗·哈夫曼-拉罗切有限公司 Method for detecting polyspecific conjugate
CN104736706A (en) 2012-08-24 2015-06-24 中外制药株式会社 FcgammaRIIb-specific Fc region variant
LT2900694T (en) 2012-09-27 2018-11-12 Merus N.V. Bispecific igg antibodies as t cell engagers
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR20200134340A (en) 2013-01-10 2020-12-01 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
JP6466904B2 (en) 2013-03-15 2019-02-06 ヤンセン バイオテツク,インコーポレーテツド Interferon alpha and omega antibody antagonists
US9157910B2 (en) 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
LT2976361T (en) 2013-03-18 2018-10-25 Biocerox Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
US20160039912A1 (en) 2013-04-02 2016-02-11 Chugai Seiyaku Kabushiki Kaisha Fc REGION VARIANT
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
JP2016519135A (en) * 2013-05-10 2016-06-30 ヌマブ アクチェンゲゼルシャフト Bispecific constructs and their use in the treatment of various diseases
JP6534615B2 (en) 2013-09-27 2019-06-26 中外製薬株式会社 Method for producing polypeptide heteromultimer
JPWO2015046554A1 (en) 2013-09-30 2017-03-09 中外製薬株式会社 Method for producing antigen-binding molecule using modified helper phage
MX2016005781A (en) 2013-11-04 2016-07-18 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins.
EA034655B1 (en) 2013-11-06 2020-03-03 Янссен Байотек, Инк. Anti-ccl17 antibodies
AU2014347565B2 (en) 2013-11-11 2020-08-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
TWI702316B (en) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 Antigen-binding molecules and their database that change antigen-binding ability in response to compound concentration
EP3514179A1 (en) 2014-01-24 2019-07-24 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CA2941030A1 (en) 2014-02-28 2015-09-03 Merus N.V. Antibodies that bind egfr and erbb3
TWI697500B (en) 2014-03-14 2020-07-01 瑞士商諾華公司 Antibody molecules to lag-3 and uses thereof
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CA2943707A1 (en) * 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
EP3143154B1 (en) * 2014-05-10 2020-01-29 Sorrento Therapeutics, Inc. Chemically-locked bispecific antibodies
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
PE20170519A1 (en) 2014-06-23 2017-05-11 Janssen Biotech Inc ANTIBODIES ANTAGONISTS OF INTERFERON ALPHA AND OMEGA
CA2952727A1 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific nkp46 binding proteins
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
RU2017105160A3 (en) 2014-07-21 2019-02-18
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
JP2017524367A (en) 2014-08-14 2017-08-31 ノバルティス アーゲー Treatment of cancer using GFRα-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
CN106999604A (en) 2014-09-02 2017-08-01 伊缪诺金公司 Method for preparing antibody drug conjugate composition
EP3191187A4 (en) 2014-09-09 2018-04-04 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
RU2017113731A3 (en) 2014-09-26 2019-09-20
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
UY36351A (en) 2014-10-14 2016-06-01 Novartis Ag ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME
JP6681396B2 (en) 2014-11-17 2020-04-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Method of treating a tumor with a CD3XCD20 bispecific antibody
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
EP3233907A1 (en) 2014-12-19 2017-10-25 Genmab A/S Rodent bispecific heterodimeric proteins
AU2016205974A1 (en) 2015-01-08 2017-07-13 Biontech Ag Agonistic TNF receptor binding agents
US10774156B2 (en) 2015-01-22 2020-09-15 Eli Lilly And Company IgG bispecific antibodies and processes for preparation
CN104818295A (en) * 2015-02-03 2015-08-05 武汉友芝友生物制药有限公司 Method for preparing and screening cell line expressing bispecific antibody
CN112142844A (en) 2015-02-05 2020-12-29 中外制药株式会社 Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
EP3056512A1 (en) 2015-02-10 2016-08-17 Medizinische Universität Wien Antibody construct
JP6773679B2 (en) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Heavy chain constant region with reduced binding to the Fc gamma receptor
WO2016159213A1 (en) * 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
WO2016164731A2 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI687228B (en) * 2015-05-11 2020-03-11 美商索倫多醫療公司 Chemically-locked bispecific antibodies
CN104865389B (en) * 2015-05-28 2017-06-06 卫生部北京医院 A kind of method and kit for detecting human serum heterozygosis light chain antibody
CN107708734A (en) 2015-06-22 2018-02-16 詹森生物科技公司 With the antibody of AntiCD3 McAb 8 and survivin inhibitor therapeutic alliance ferroheme malignant tumour
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CA2988806A1 (en) 2015-06-29 2017-01-05 Immunogen, Inc. Conjugates of cysteine engineered antibodies
EP3319996A1 (en) 2015-07-09 2018-05-16 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
EP3345928B1 (en) 2015-07-10 2020-06-24 Merus N.V. Human cd3 binding antibody
EP3317301A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
BR112018002432A2 (en) 2015-09-18 2018-09-18 Chugai Pharmaceutical Co Ltd il-8 binding antibodies and uses thereof
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3370770B1 (en) 2015-11-03 2021-01-20 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US20190077872A1 (en) 2015-11-18 2019-03-14 Chugai Seiyaku Kabushiki Kaisha Method for enhancing humoral immune response
US20180326058A1 (en) 2015-11-18 2018-11-15 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
EP3389712A1 (en) 2015-12-17 2018-10-24 Novartis AG Antibody molecules to pd-1 and uses thereof
CA3007421A1 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
EP3390453A2 (en) 2015-12-17 2018-10-24 Janssen Biotech, Inc. Antibodies specifically binding hla-dr and their uses
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
BR112018014760A2 (en) 2016-01-22 2018-12-26 Janssen Biotech Inc anti-ror1 antibodies, bispecific antibodies to ror1 x cd3 and methods of use
WO2017129790A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
CN108699154A (en) 2016-02-26 2018-10-23 国家医疗保健研究所 There is the antibody and application thereof of specificity to BTLA
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
MX2018010988A (en) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy.
CN109641955A (en) 2016-03-22 2019-04-16 国家医疗保健研究所 Anti- claudin-1 antibody of humanization and application thereof
US20200291354A1 (en) 2016-03-23 2020-09-17 Danielle Alexandra Cook Cell secreted minibodies and uses thereof
WO2017181119A2 (en) 2016-04-15 2017-10-19 Novartis Ag Compositions and methods for selective protein expression
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
KR20180134893A (en) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for making antibodies based on the use of expression-enhancing loci
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3474895A1 (en) 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
SG11201900344YA (en) 2016-07-15 2019-02-27 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3032054A1 (en) 2016-07-28 2018-02-01 Novartis Ag Combination therapies of chimeric antigen receptors and pd-1 inhibitors
BR112019001693A2 (en) 2016-07-29 2019-07-02 Ct Hospitalier Universitaire Toulouse antibodies targeting tumor-associated macrophages and their uses
RU2019105693A (en) 2016-08-01 2020-09-01 Новартис Аг TREATMENT OF CANCER USING ANTIGENIC CHIMERIC RECEPTOR IN COMBINATION WITH A MOLECULE INHIBITOR PROMOTING THE M2 PHENOTYPE OF MACROPHAG
WO2018036947A1 (en) 2016-08-22 2018-03-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inhibiting biological responses induced by a receptor that uses pi3k to signal in a cell
AU2017341047A1 (en) 2016-10-07 2019-05-02 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EA201990787A1 (en) 2016-11-02 2019-12-30 Энгмаб Сарл Specific antibody to bcma and cd3 and immunological medicine for combined use in treatment of multiple myeloma
GB201619652D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel polypeptides
KR20190104995A (en) 2016-11-23 2019-09-11 이뮤노젠 아이엔씨 Selective Sulfonation of Benzodiazepines Derivatives
EP3574005A1 (en) 2017-01-26 2019-12-04 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018158719A1 (en) 2017-03-02 2018-09-07 Novartis Ag Engineered heterodimeric proteins
JP2020510432A (en) 2017-03-02 2020-04-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Antibodies with specificity for NECTIN-4 and uses thereof
MX2019010583A (en) 2017-03-09 2019-11-25 Genmab As Antibodies against pd-l1.
CA3057907A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
MX2019011858A (en) 2017-04-03 2019-11-21 Oncologie Inc Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents.
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN110709421A (en) 2017-05-02 2020-01-17 鳄鱼生物科学公司 Bispecific antibodies against OX40 and CTLA-4
UY37758A (en) 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
TW201920258A (en) 2017-06-21 2019-06-01 美商基利科學股份有限公司 Multispecific antibodies that target HIV GP120 and CD3
CU20190109A7 (en) 2017-06-22 2020-10-20 Novartis Ag ANTIBODY MOLECULES THAT BIND CD73
CN111050791A (en) 2017-06-27 2020-04-21 诺华股份有限公司 Dosing regimens for anti-TIM-3 antibodies and uses thereof
CN111163798A (en) 2017-07-20 2020-05-15 诺华股份有限公司 Dosing regimens for anti-LAG-3 antibodies and uses thereof
CN111406067A (en) 2017-08-04 2020-07-10 健玛保 Binding agents that bind to PD-L1 and CD137 and uses thereof
WO2019057933A1 (en) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
SG11202002508XA (en) * 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
BR112020007154A2 (en) 2017-10-20 2020-09-29 F. Hoffmann-La Roche Ag method for producing a heterodimeric polypeptide and polypeptides
CA3078676A1 (en) 2017-10-30 2019-05-09 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
EP3710053A1 (en) 2017-11-16 2020-09-23 Novartis AG Combination therapies
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
US20190218310A1 (en) 2017-12-22 2019-07-18 Argenx Bvba Bispecific antigen binding construct
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019175198A2 (en) 2018-03-12 2019-09-19 Genmab A/S Antibodies
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
WO2019200229A1 (en) 2018-04-13 2019-10-17 Novartis Ag Dosage regimens for anti-pd-l1 antibodies and uses thereof
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
WO2019226617A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
SG11202010579XA (en) 2018-06-01 2020-12-30 Novartis Ag Binding molecules against bcma and uses thereof
CN112203725A (en) 2018-06-13 2021-01-08 诺华股份有限公司 BCMA chimeric antigen receptors and uses thereof
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
WO2020012337A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
WO2020068774A1 (en) 2018-09-24 2020-04-02 The Medical College Of Wisconsin, Inc. System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
WO2020070062A1 (en) 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2020094609A1 (en) 2018-11-06 2020-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
WO2020094744A1 (en) 2018-11-06 2020-05-14 Genmab A/S Antibody formulation
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128892A1 (en) 2018-12-20 2020-06-25 Novartis Ag Extended low dose regimens for mdm2 inhibitors
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020148677A1 (en) 2019-01-18 2020-07-23 Janssen Biotech, Inc. Gprc5d chimeric antigen receptors and cells expressing the same
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020188086A1 (en) 2019-03-20 2020-09-24 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
WO2020205523A1 (en) 2019-03-29 2020-10-08 Atarga, Llc Anti fgf23 antibody
WO2020236795A2 (en) 2019-05-21 2020-11-26 Novartis Ag Trispecific binding molecules against bcma and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
WO2020243477A2 (en) 2019-05-30 2020-12-03 Amgen Inc. Engineering the hinge region to drive antibody dimerization
WO2021009263A1 (en) 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AT158021T (en) 1990-08-29 1997-09-15 Genpharm Int Production and use of non-human transgents for producing heterological antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH08509612A (en) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド Transgenic non-human animal capable of producing heterologous antibody
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3266276B2 (en) * 1996-07-25 2002-03-18 ゲーエスエフ―フォルシュングスツェントゥルム・フューア・ウムヴェルト・ウント・ゲズントハイト・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Simplified production of bispecific antibody fragments
US20040038894A1 (en) * 1996-12-31 2004-02-26 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Compounds for modulating cell negative regulations and biological applications thereof
DE69830901T2 (en) 1997-05-02 2006-05-24 Genentech Inc., San Francisco A method for producing multispecific antibodies having heteromultimeric and common components
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
DE19859110A1 (en) * 1998-09-25 2000-04-13 Horst Lindhofer Bispecific and trispecific antibodies that react specifically with inducible surface antigens as operational targets
AT255420T (en) * 1998-09-25 2003-12-15 Horst Lindhofer Use of tumor cells time-related in combination with intake antibodies for immunization
US20050208519A1 (en) * 2004-03-12 2005-09-22 Genenews Inc. Biomarkers for diagnosing schizophrenia and bipolar disorder
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA02000962A (en) 1999-07-29 2002-07-02 Medarex Inc Human monoclonal antibodies to her2 neu.
KR100942863B1 (en) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 Human ctla-4 antibodies and their uses
PT1354034E (en) 2000-11-30 2008-02-28 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
WO2002100348A2 (en) 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EA201492217A1 (en) * 2002-10-17 2015-06-30 Генмаб А/С HUMAN MONOCLONAL ANTIBODIES AGAINST CD20
JP2006524039A (en) * 2003-01-09 2006-10-26 マクロジェニクス,インコーポレーテッド Identification and production of antibody containing mutant Fc region and use thereof
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN1842538B (en) * 2003-06-27 2013-06-12 比奥根艾迪克Ma公司 Modified binding molecules comprising connecting peptides
WO2005042582A1 (en) * 2003-11-04 2005-05-12 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
JP2007515493A (en) 2003-12-22 2007-06-14 セントカー・インコーポレーテツド Method for generating multimeric molecules
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
JP5553963B2 (en) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド Methods for refolding recombinant antibodies
TWI671403B (en) 2005-03-31 2019-09-11 中外製藥股份有限公司 Method for controlling controlled assembly of polypeptide
JP5525729B2 (en) * 2005-11-28 2014-06-18 ゲンマブ エー/エス Recombinant monovalent antibody and production method thereof
AU2007224228B2 (en) * 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
ES2667863T3 (en) * 2007-03-29 2018-05-14 Genmab A/S Bispecific antibodies and their production methods
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
JP5570974B2 (en) 2007-05-31 2014-08-13 ゲンマブ エー/エス Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
WO2010063785A2 (en) 2008-12-03 2010-06-10 Genmab A/S Antibody variants having modifications in the constant region
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
CN103097417B (en) 2010-04-20 2019-04-09 根马布股份公司 Albumen of the FC containing heterodimeric antibodies and preparation method thereof
MX346731B (en) 2010-04-23 2017-03-30 Genentech Inc * Production of heteromultimeric proteins.
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP6167040B2 (en) 2010-11-05 2017-07-19 ザイムワークス,インコーポレイテッド Design of stable heterodimeric antibodies with mutations in the Fc domain
WO2012104344A1 (en) * 2011-02-01 2012-08-09 Genmab A/S Human antibodies and antibody-drug conjugates against cd74
CA2828811A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN110964115A (en) 2011-10-27 2020-04-07 健玛保 Production of heterodimeric proteins
RS61057B1 (en) 2012-11-21 2020-12-31 Janssen Biotech Inc Bispecific egfr/c-met antibodies
US9595164B2 (en) 2013-05-16 2017-03-14 Bally Gaming, Inc. Social gaming website and related in-advertisement gaming

Also Published As

Publication number Publication date
CN104497143B (en) 2020-08-25
AU2008234248B2 (en) 2014-07-10
CN101802015A (en) 2010-08-11
JP5681482B2 (en) 2015-03-11
CN104497143A (en) 2015-04-08
US9212230B2 (en) 2015-12-15
CN101802015B (en) 2015-05-06
ES2667863T3 (en) 2018-05-14
CA2681974A1 (en) 2008-10-09
AU2008234248A1 (en) 2008-10-09
US10906991B2 (en) 2021-02-02
AU2008234248C1 (en) 2015-01-22
WO2008119353A1 (en) 2008-10-09
ES2593484T3 (en) 2016-12-09
US20100105874A1 (en) 2010-04-29
CA2681974C (en) 2019-12-31
WO2008119353A8 (en) 2009-07-30
MX2009010282A (en) 2009-10-12
US20160159930A1 (en) 2016-06-09
EP2139924B1 (en) 2016-07-06
IL201082A (en) 2017-04-30
NZ614857A (en) 2015-04-24
EP2139924A1 (en) 2010-01-06
EP2626372A1 (en) 2013-08-14
JP2010522701A (en) 2010-07-08
JP2014239689A (en) 2014-12-25
EP2626372B1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
HRP20182174T1 (en) Engineered anti-il-23p19 antibodies
HK1217217A1 (en) Antibody modification method for purifying bispecific antibody
IL250624D0 (en) Anti-fgfr3 antibodies and methods using same
HRP20160190T1 (en) Anti-igf antibodies
HRP20160684T1 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
HK1203901A1 (en) Method for producing patterned materials
HRP20140727T1 (en) Bivalent, bispecific antibodies
HRP20140376T1 (en) Bispecific anti-vegf/anti-ang-2 antibodies
HRP20140258T1 (en) Bispecific antigen binding proteins
HK1182625A1 (en) Bispecific antibodies
HRP20140108T1 (en) Anti-sclerostin antibodies
HRP20140153T1 (en) Anti-sclerostin antibodies
IL244197D0 (en) Anti-cd100 antibodies and methods for using the same
HRP20120759T1 (en) Cross-species-specific bispecific binders
HRP20160404T1 (en) Method for producing platelets
IL233563D0 (en) Bispecific anti-her antibodies
HRP20150937T1 (en) Penta-specific antibody
ZA201001753B (en) Method for consumer-dispenser interactions
ZA201102119B (en) Improved antibody libraies
HK1138942A1 (en) Method
IL206161D0 (en) Bivalent, bispecific antibodies
IL205750D0 (en) Bivalent, bispecific antibodies
IL205285D0 (en) Bivalent, bispecific antibodies
IL215062D0 (en) Bispecific anti-erbb-3/anti-c-met antibodies
HRP20161548T1 (en) Antibodies against il-25

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed